The latest new contracts, like ImmunoPrecise Antibodies (Europe) B.V’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
Oct 02, 2024•over 1 year ago
Contract Type
agreement
VictoriaBiotechnologyTherapeutics
Description
ImmunoPrecise Antibodies Ltd. and Biotheus Inc. have entered into a Material Transfer and Evaluation Agreement (MTEA) concerning a Talem therapeutic antibody asset for the development of a bispecific therapy against solid tumors. Under the agreement, Biotheus will have the rights to further evaluate the suitability of Talem’s AI-enhanced TATX-20 lead candidate for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors.
Company Information
Company
ImmunoPrecise Antibodies (Europe) B.V
Location
Victoria, British Columbia, Canada
About
ImmunoPrecise Antibodies (Europe) B.V. specializes in antibody discovery, engineering, and characterization services. It operates in Europe and has advanced capabilities for recombinant protein expression. The company is a carve-out from ImmunoPrecise Antibodies Ltd.
VictoriaBiotechnologyTherapeutics